Changchang Lu
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer.
Journal: Frontiers in immunology
Published: December 22, 2025
Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer.
Journal: Frontiers in immunology
Published: August 27, 2025
An Immunomodulator-Boosted Lactococcus Lactis Platform For Enhanced In Situ Tumor Vaccine.
Journal: Advanced healthcare materials
Published: May 03, 2024
Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V.
Journal: Biomolecules & biomedicine
Published: March 04, 2024
Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors.
Journal: Biomaterials
Published: November 22, 2023
Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.
Journal: Frontiers in immunology
Published: April 23, 2023
Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer.
Journal: Human vaccines & immunotherapeutics
Published: February 22, 2023
Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines.
Journal: Frontiers in immunology
Published: December 16, 2022
Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort.
Journal: Human vaccines & immunotherapeutics
Published: November 22, 2022
PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial.
Journal: Cell reports. Medicine
Published: October 24, 2022
Last Updated: 09/26/2026